Mankind Pharma is a prominent pharmaceutical company in India, specializing in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations, including both acute and chronic therapeutic areas.

The company reported a significant revenue increase of 20.8% year-on-year in Q2 FY26, attributed to robust growth in its domestic business and strategic acquisitions, notably Bharat Serums and Vaccines (BSV).

Despite challenges from GST rollouts and strong monsoons impacting their OTC segment, Mankind Pharma exhibited resilience, reporting a notable 83% growth in export revenues due to strategic integration of BSV.

Mankind Pharma is focused on expanding its chronic and specialty segments, which have outperformed market growth rates, particularly in cardiac and anti-diabetes therapies.

In line with its long-term sustainability goals, Mankind Pharma has increased its use of renewable power significantly and enhanced waste management processes, showing its commitment to ESG initiatives.